Wall Street brokerages expect TearLab Corporation (NASDAQ:TEAR) to post earnings per share (EPS) of ($0.73) for the current fiscal quarter, according to Zacks. Three analysts have made estimates for TearLab Corporation’s earnings, with the highest EPS estimate coming in at ($0.69) and the lowest estimate coming in at ($0.77). TearLab Corporation posted earnings per share of ($1.00) during the same quarter last year, which would indicate a positive year-over-year growth rate of 27%. The company is scheduled to announce its next quarterly earnings results on Wednesday, August 2nd.

According to Zacks, analysts expect that TearLab Corporation will report full-year earnings of ($2.75) per share for the current financial year, with EPS estimates ranging from ($2.88) to ($2.62). For the next financial year, analysts expect that the company will post earnings of ($1.39) per share. Zacks’ EPS calculations are a mean average based on a survey of analysts that follow TearLab Corporation.

TearLab Corporation (NASDAQ:TEAR) last released its earnings results on Monday, May 15th. The medical research company reported ($0.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by $0.07. The company had revenue of $6.70 million for the quarter, compared to analyst estimates of $7.02 million. The firm’s revenue for the quarter was down 1.5% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.21) EPS.

A number of research analysts recently issued reports on TEAR shares. Zacks Investment Research raised shares of TearLab Corporation from a “sell” rating to a “hold” rating in a research report on Thursday, March 16th. HC Wainwright set a $12.00 price target on shares of TearLab Corporation and gave the company a “buy” rating in a research report on Sunday, March 12th. Finally, Rodman & Renshaw lowered their price target on shares of TearLab Corporation from $12.00 to $4.00 and set a “buy” rating for the company in a research report on Tuesday, May 16th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. TearLab Corporation has an average rating of “Buy” and a consensus target price of $5.05.

COPYRIGHT VIOLATION NOTICE: This news story was posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US & international trademark and copyright law. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/07/10/0-73-earnings-per-share-expected-for-tearlab-corporation-tear-this-quarter.html.

TearLab Corporation (TEAR) traded up 1.76% during trading on Monday, reaching $1.73. 1,510 shares of the company traded hands. TearLab Corporation has a 12-month low of $1.55 and a 12-month high of $9.00. The firm’s 50 day moving average price is $1.90 and its 200 day moving average price is $3.62. The firm’s market capitalization is $9.92 million.

TearLab Corporation Company Profile

TearLab Corporation is an in-vitro diagnostic company. The Company has commercialized a tear testing platform, the TearLab Osmolarity System, which enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company, through its subsidiary TearLab Research, Inc, develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites, genes and proteins) at the point-of-care.

Get a free copy of the Zacks research report on TearLab Corporation (TEAR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for TearLab Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TearLab Corporation and related companies with MarketBeat.com's FREE daily email newsletter.